Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of April 30, 2025 • 1:41 PM ET

Date/Time Source News Release
04/27/2025 03:00 PM EDT GlobeNewswire Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting
04/25/2025 07:35 AM EDT GlobeNewswire Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma
03/04/2025 06:35 AM EST GlobeNewswire Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
03/03/2025 07:30 AM EST GlobeNewswire Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
02/20/2025 04:05 PM EST GlobeNewswire Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025
02/06/2025 07:30 AM EST GlobeNewswire Y-mAbs to Present at the Oppenheimer 35?? Annual Life Sciences Conference
01/31/2025 07:35 AM EST GlobeNewswire Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting
01/10/2025 09:26 AM EST GlobeNewswire Correcting & Replacing - Y-mAbs Provides Strategic Business Update and 2025 Priorities
01/10/2025 07:35 AM EST GlobeNewswire Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit
01/10/2025 07:05 AM EST GlobeNewswire Y-mAbs Provides Strategic Business Update and 2025 Priorities
Page